Conclusion: PTPN22, miR-181a and miR-181b might be involved in progression of Jurkat cells and targeting these molecules by RNAi might confer promising tool in treatment of T-ALL. This evidence concerns the gene PTPN22 and acute lymphoblastic leukemia.